Aldeyra Therapeutics, Inc.

ALDX Nasdaq SEC CIK 1341235
Follow Aldeyra Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$3.8M +51.1% vs same quarter last year
EPS, diluted −$0.06 +53.8% vs same quarter last year
Operating cash flow −$4.1M +41.3% vs same quarter last year
Operating income −$4.1M +48.3% vs same quarter last year
Net income by quarter
−$15.8M
−$9.9M
−$9.8M
−$7.7M
−$6.5M
−$3.5M
−$5.5M
−$3.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$80M−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$33.8M
FY24−$55.9M
FY23−$37.5M
FY22−$62M
FY21−$57.8M
FY20−$37.6M
FY19−$60.8M
FY18−$38.9M
FY17−$22.3M
FY16−$18.7M
FY15−$12.1M
FY14−$5.2M
FY13-
FY12−$23.1M
FY11−$2.4M
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23−$30.3M
FY22−$56.7M
FY21−$42.6M
FY20-
FY19−$45M
FY18−$30.1M
FY17−$19.2M
FY16−$15.2M
FY15−$9.4M
FY14−$4.8M
FY13-
FY12-
FY11-